Follow calcium between bone, kidney, and intestine; interpret PTH in context; and distinguish urgent calcium disorders from chronic mineral disease.
Calcium is high and PTH is inside the laboratory reference range. Is that reassuring? No: a healthy parathyroid response to hypercalcemia is suppression. A numerically normal PTH can therefore be physiologically inappropriate. Interpret the hormone against the calcium concentration before deciding which disease name fits.
First establish whether biologically active calcium is actually abnormal. Then ask whether PTH is responding appropriately, and use phosphate, magnesium, kidney function, vitamin D, medicines, and urine calcium to explain the pattern.
Follow calcium through three organs
Circulating calcium includes an ionized fraction, an albumin-bound fraction, and calcium complexed to anions. Ionized calcium is the immediately active fraction. Low albumin can lower total calcium without causing true hypocalcemia. Albumin-correction equations are estimates and perform poorly in some settings, especially critical illness and kidney disease. When symptoms and total calcium disagree, or binding and pH are changing, measure ionized calcium directly. Alkalosis increases albumin binding and can lower ionized calcium even while total calcium remains unchanged. [11][1][2]
The calcium-sensing receptor on parathyroid chief cells detects extracellular calcium. Falling calcium normally stimulates PTH. The hormone increases renal calcium conservation, reduces proximal tubular phosphate reabsorption, and stimulates renal production of active vitamin D. At bone, PTH signaling in osteoblast-lineage cells regulates osteoclast formation and activity through mediators including RANKL; it should not be drawn as direct PTH activation of an osteoclast receptor. Sustained excess favors resorption, whereas intermittent therapeutic exposure has different skeletal effects. [11]
How PTH raises calcium while usually lowering phosphate
Bone
PTH acts on osteoblast-lineage cells. RANKL signaling increases osteoclast-mediated resorption. Calcium and phosphate enter extracellular fluid.
Kidney
More calcium is reabsorbed in the distal nephron. Less phosphate is reabsorbed proximally. More 25-hydroxyvitamin D becomes calcitriol.
Intestine
Calcitriol increases absorption of both calcium and phosphate. This is an indirect intestinal effect of PTH.
With functioning kidneys, phosphate loss in urine usually outweighs the phosphate supplied by bone and gut. Advanced kidney failure changes that balance.
Vitamin D from skin synthesis or intake is converted in the liver to 25-hydroxyvitamin D, then chiefly in the kidney to 1,25-dihydroxyvitamin D, or calcitriol. Measure 25-hydroxyvitamin D to assess nutritional status. Calcitriol is tightly regulated and can be normal or elevated during nutritional deficiency because secondary PTH elevation stimulates its production; it is not a substitute status test.
Poor mineral availability impairs mineralization, producing rickets at growing plates and osteomalacia in adults. Rickets can cause bowed legs, widened wrists, enlargement of costochondral junctions (rachitic rosary), and softened skull bones (craniotabes). Adult osteomalacia can produce bone pain, proximal weakness, and radiographic pseudofractures. These findings require biochemical evaluation of the underlying mineral defect. [12][3]
Thyroid C cells secrete calcitonin. It can inhibit osteoclast activity, but its role in routine adult calcium homeostasis is modest compared with PTH and vitamin D. Pharmacological calcitonin can lower calcium quickly for a short interval. A calcitonin measurement also has a distinct role in evaluating medullary thyroid carcinoma; an elevation alone is not pathognomonic and must be interpreted with the clinical and assay context.
Calcitonin and CEA can support surveillance. Germline RET disease links medullary carcinoma with MEN2: MEN2A can include primary hyperparathyroidism, whereas MEN2B has a different phenotype including mucosal neuromas. Both syndromes require assessment for pheochromocytoma before thyroid surgery. [4][10]
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 4
Show answer and explanations for case 4
A. FHH as the explanation for low phosphate and bone pain. (Why this does not fit)
FHH typically causes mild hypercalcemia; it does not explain this deficiency and mineralization pattern.
B. Vitamin D deficiency is excluded by normal calcitriol. (Why this does not fit)
Calcitriol is regulated and is not the preferred nutritional status measurement.
C. Vitamin D deficiency with secondary hyperparathyroidism and impaired mineralization. (Best answer)
A preserved calcitriol concentration does not exclude depleted vitamin D stores because PTH can stimulate its production.
D. Primary hypoparathyroidism. (Why this does not fit)
PTH is elevated rather than deficient, and phosphate is low rather than retained.
Takeaway: Use 25-hydroxyvitamin D for nutritional status and distinguish osteomalacia from low bone density alone.
Confirm an unexpected elevation with appropriate repeat total or ionized testing. Review dehydration, albumin, kidney function, supplements, and medicines. Hypercalcemia can cause polyuria, thirst, constipation, nausea, cognitive changes, weakness, and a shortened QT interval. Symptom severity depends on concentration, rate of rise, and the patient's condition. A PTH result that is high or insufficiently suppressed during confirmed hypercalcemia directs attention toward primary hyperparathyroidism, familial hypocalciuric hypercalcemia, lithium effects, or tertiary disease in an appropriate renal history. [1]
Primary hyperparathyroidism commonly reflects a parathyroid adenoma, although multigland disease and rare carcinoma occur. The phenotype ranges from an incidental biochemical finding to nephrolithiasis, reduced bone density, fractures, and marked skeletal resorption with brown tumors. Low phosphate supports PTH-mediated renal phosphate loss but is not obligatory, particularly with impaired kidney function.
Familial hypocalciuric hypercalcemia usually produces longstanding mild hypercalcemia with relatively low urine calcium and a nonsuppressed PTH. A family history or early-life records can be useful. The calcium-to-creatinine clearance ratio is calculated as urine calcium × serum creatinine divided by serum calcium × urine creatinine, using compatible units and paired samples. A ratio below 0.01 favors FHH, but overlap with primary hyperparathyroidism is substantial. Vitamin D deficiency, low calcium intake, kidney disease, lithium, and thiazides can lower urinary calcium. Do not send a patient to surgery from one ratio without evaluating these limitations and considering genetic testing when indicated. [1]
Parathyroid imaging localizes abnormal glands after a biochemical diagnosis and a decision to operate; it does not diagnose primary hyperparathyroidism. Surgery is recommended for symptomatic disease and for selected asymptomatic patients, including those younger than 50 or with calcium more than 1 mg/dL above the upper limit, osteoporosis or vertebral fracture, kidney impairment, stones, or guideline-defined hypercalciuria. The choice also incorporates operative suitability and patient preference. A sestamibi focus cannot replace this assessment.
When PTH is suppressed, seek a different driver. PTH-related peptide from malignancy stimulates PTH-receptor pathways while endogenous PTH falls. Osteolytic malignancy, including myeloma, can release calcium through local bone destruction. Granulomatous disease and some lymphomas can produce excessive calcitriol outside normal renal regulation. Excess vitamin D intake more often markedly raises 25-hydroxyvitamin D. Calcium-alkali exposure, immobilization, thyrotoxicosis, vitamin A excess, and adrenal insufficiency also belong in the differential when the history supports them.
Review thiazides, which reduce urinary calcium, and lithium, which commonly produces nonsuppressed PTH, separately rather than assigning every medication effect to the suppressed-PTH category. [11] Paget disease alone usually does not cause hypercalcemia; a MEN1 association between gastrinoma and parathyroid disease does not make Zollinger-Ellison syndrome a direct calcium-raising mechanism. [4][5]
Low calcium: distinguish missing PTH from resistance
Hypocalcemia can cause perioral tingling, cramps, carpopedal spasm, seizures, laryngospasm, and QT prolongation. Chvostek and Trousseau signs support neuromuscular irritability but are not sufficient to establish the biochemical diagnosis. Obtain calcium, magnesium, phosphate, renal function, and PTH. A low or inappropriately normal PTH during hypocalcemia suggests inadequate secretion. An elevated PTH means the gland is responding, but the response may be limited by vitamin D deficiency, renal disease, or resistance. [2]
Neck surgery is an important cause of hypoparathyroidism. Other causes include autoimmune disease, congenital gland-development disorders such as 22q11.2 deletion, and infiltrative injury. Low PTH reduces phosphate excretion, so hypocalcemia with high phosphate is a useful pattern. [13] Current international guidance defines chronic postsurgical hypoparathyroidism as persisting beyond 12 months, allowing for later recovery than the older six-month definition. [6]
Severe magnesium deficiency can impair both PTH secretion and tissue responsiveness. Calcium may remain difficult to correct until magnesium is replenished. This does not mean delaying intravenous calcium in a patient with seizures, laryngospasm, or serious ECG abnormalities: correct the immediate calcium emergency and magnesium deficit together.
Pseudohypoparathyroidism refers to disorders of PTH signaling. Hypocalcemia, hyperphosphatemia, and high PTH with preserved renal function suggest resistance once relevant alternatives are assessed. In classic PHP1A, a maternal GNAS defect can cause renal PTH resistance together with Albright hereditary osteodystrophy: short stature, brachydactyly, and sometimes subcutaneous ossification and early obesity. Tissue-specific imprinting matters; the same kind of defect on the paternal allele can produce a skeletal phenotype without the same hormone resistance, historically termed pseudopseudohypoparathyroidism. PHP1B often involves imprinting abnormalities and may lack the classic skeletal appearance. Do not describe every tissue as uniformly unresponsive. [7]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 20
Show answer and explanations for case 20
A. Pseudopseudohypoparathyroidism without hormone resistance. (Why this does not fit)
The elevated PTH with low calcium and high phosphate demonstrates a biochemical resistance pattern.
B. Postsurgical hypoparathyroidism. (Why this does not fit)
There is no surgical history, and deficient glands would produce low or inappropriate normal PTH.
C. PHP1A with Albright hereditary osteodystrophy and hormone resistance. (Best answer)
The phenotype plus maternal GNAS involvement and high-PTH hypocalcemia supports this diagnosis.
D. Primary hyperparathyroidism. (Why this does not fit)
High PTH with low calcium is not the usual primary hyperparathyroid pattern.
Takeaway: Combine phenotype, parental origin, and biochemical resistance.
Kidney disease changes the expected phosphate pattern
In chronic kidney disease, declining calcitriol production, altered phosphate handling, and rising FGF23 contribute to secondary hyperparathyroidism. Serum phosphate can remain normal early because compensatory mechanisms increase excretion per functioning nephron. Later, phosphate retention becomes more evident. Calcium is often normal or low, and PTH rises in response to the disturbed environment. Interpret trends in calcium, phosphate, and PTH together instead of treating one mildly elevated PTH result in isolation. [8]
Correct modifiable contributors, including excessive phosphate intake, vitamin D deficiency, and hypocalcemia when appropriate. In adults with nondialysis CKD, calcitriol or active analogues are not routinely indicated for every PTH elevation; they may be reserved for severe progressive hyperparathyroidism in advanced disease. Phosphate binders such as sevelamer reduce intestinal phosphate absorption when taken with food and do not add calcium. Calcimimetics such as cinacalcet increase calcium-sensing-receptor sensitivity and lower PTH, but can cause hypocalcemia.
After longstanding secondary stimulation, parathyroid secretion may become autonomous, producing tertiary hyperparathyroidism with hypercalcemia. Phosphate depends on current kidney function: it may remain high in advanced kidney failure but can be low after a successful transplant because PTH-driven phosphate wasting persists. A rule that tertiary disease always has high phosphate would misclassify this important setting. [14]
Stabilize dangerous calcium while treating its cause
Severe or symptomatic hypercalcemia requires prompt assessment and treatment. Isotonic fluid restores volume when the patient is depleted, with careful reassessment in heart or kidney failure. Loop diuretics are not routine calcium-lowering treatment; use them when clinically indicated for fluid overload. For hypercalcemia of malignancy, intravenous bisphosphonate or denosumab provides antiresorptive treatment. For adults with severe malignancy-associated hypercalcemia above 14 mg/dL, the Endocrine Society conditionally suggests adding injectable calcitonin to an intravenous bisphosphonate or denosumab.
The certainty of evidence is very low; calcitonin can provide earlier lowering while the longer-acting drug takes effect. Limit calcitonin to 48-72 hours because tachyphylaxis develops; intranasal osteoporosis dosing is not the acute emergency regimen. Treat the malignancy itself as well. [4][5]
Calcitriol-mediated hypercalcemia often responds to glucocorticoids because they reduce extrarenal calcitriol production. Persistent severe malignancy-associated disease may also need antiresorptive therapy. Choose treatment from the mechanism and severity, with renal function and hypocalcemia risk informing drug selection.
Severe symptomatic hypocalcemia requires monitored intravenous calcium, commonly calcium gluconate, while the cause is assessed. Stable chronic hypoparathyroidism is usually treated with oral calcium and active vitamin D, targeting symptom control with calcium in the lower normal range or just below it while avoiding hypercalciuria and renal complications. Maintain appropriate nutritional vitamin D and magnesium as well; ordinary vitamin D is not biologically useless, although it does not replace the need for active vitamin D in many patients with deficient PTH. [2][6]
For adults inadequately controlled with conventional therapy, PTH replacement may be considered under specialist care. The FDA approved palopegteriparatide in 2024 for adult hypoparathyroidism; it is not an immediate rescue treatment for a newly postoperative tetany episode. Its label requires structured calcium monitoring and dose adjustment because both hypo- and hypercalcemia can occur. [9]
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 27
Show answer and explanations for case 27
A. Increase oral calcium supplementation without using urinary calcium to guide dosing. (Why this does not fit)
Further calcium loading can worsen renal complications.
B. Give a long-acting PTH analogue as a rescue dose without subsequent calcium monitoring. (Why this does not fit)
PTH replacement requires a planned transition and calcium surveillance; it is not an unmonitored emergency injection.
C. Replace calcitriol with nutritional vitamin D alone to correct the hypercalciuria. (Why this does not fit)
Nutritional vitamin D status matters, but deficient PTH can limit activation. Changing treatment requires a monitored strategy that preserves calcium control.
D. Consider approved PTH replacement, such as palopegteriparatide, with structured calcium monitoring. (Best answer)
Inadequate conventional control can justify considering replacement, but careful titration and safety monitoring remain necessary.
Takeaway: Long-term treatment should balance symptoms, serum calcium, and urinary calcium burden.
Use calcium and the appropriateness of PTH first, then explain phosphate, magnesium, kidney function, and treatment context.
Case 1
Show answer and explanations for case 1
A. Reduced albumin-bound calcium with preserved ionized calcium. (Best answer)
The normal measured active fraction explains why low total calcium need not indicate a calcium emergency.
B. Resistance to PTH action as the cause of the low total calcium. (Why this does not fit)
Resistance usually causes low ionized calcium with elevated PTH and phosphate. These data instead demonstrate reduced total calcium with preserved active calcium.
C. Severe hypoparathyroidism proven by total calcium alone. (Why this does not fit)
PTH and phosphate were not provided, and ionized calcium is normal.
D. Acute sequestration of circulating calcium into bone. (Why this does not fit)
Sequestration sufficient to cause active hypocalcemia would lower ionized calcium; the normal ionized measurement supports a binding-related explanation here.
Takeaway: Treat the biologically relevant abnormality, not a protein-related change in total calcium.
A. Nutritional vitamin D overdose proven by elevated calcitriol alone. (Why this does not fit)
Excess intake more typically markedly elevates the 25-hydroxy pool; this pattern favors extrarenal activation.
B. Excess PTH stimulation of renal calcitriol production. (Why this does not fit)
PTH is suppressed, making that explanation inconsistent with the measurements.
C. Extrarenal conversion of 25-hydroxyvitamin D to calcitriol in granulomatous tissue. (Best answer)
This can escape usual renal regulation and increase intestinal calcium absorption.
D. Increased renal calcitriol production from a PTHrP-secreting tumor. (Why this does not fit)
The granulomatous context and elevated calcitriol support extrarenal activation. PTHrP-mediated hypercalcemia generally does not substantially stimulate circulating calcitriol.
Takeaway: Measure the relevant vitamin D metabolite for the suspected mechanism.
A. Brachydactyly establishes maternal inheritance with impaired renal responsiveness to PTH. (Why this does not fit)
The stated paternal variant and preserved mineral response differ from the usual maternal PHP1A resistance pattern. Skeletal appearance alone does not determine parent of origin.
B. Paternal inheritance can cause skeletal changes without the renal PTH resistance of maternal inheritance. (Best answer)
Tissue-specific imprinting explains the classic pseudopseudohypoparathyroidism pattern.
C. Every GNAS variant causes the same degree of PTH resistance throughout all tissues, regardless of parental origin. (Why this does not fit)
Parental origin and tissue-specific expression materially alter the phenotype.
D. The skeletal findings must reflect vitamin D deficiency because serum calcium remains normal. (Why this does not fit)
GNAS-related skeletal effects can occur with normal calcium. Normal calcium does not establish nutritional deficiency.
Takeaway: Genetic effects are tissue-specific; similar hands do not guarantee identical endocrine disease.
A. The low phosphate demonstrates resolution of the previously elevated PTH concentration. (Why this does not fit)
PTH remains markedly elevated in the stem; restored filtration permits phosphate wasting despite persistent gland autonomy.
B. Persistent secondary stimulation from severe vitamin D deficiency alone. (Why this does not fit)
Vitamin D deficiency may contribute to PTH elevation, but marked persistent PTH with hypercalcemia after longstanding renal disease raises concern for autonomy and requires assessment.
C. Low phosphate excludes tertiary disease in every setting. (Why this does not fit)
That rule ignores restored phosphate excretion after transplantation.
D. Autonomous tertiary hyperparathyroidism remains possible with low phosphate. (Best answer)
Improved renal function permits PTH-mediated phosphate wasting, so phosphate need not remain high.
Takeaway: Interpret phosphate using current renal function, not only the historical diagnosis.
